Earendil Labs closed a $787 million financing to accelerate an AI‑driven biologics pipeline spanning autoimmune disease and oncology. The round included Dimension, Luminous Ventures and Sanofi and funds the company’s push to advance multiple candidates toward clinical testing and scale an R&D organization, CEO Jian Peng said. Earendil claims more than 40 discovery programs and listed 19 pipeline assets, with an IBD candidate ready for Phase 2. The raise positions Earendil to operate at a much larger scale across discovery and early development, enabling simultaneous advancement of bispecifics, T‑cell engagers and ADCs built with AI platforms. The deal also extends existing strategic ties with Sanofi and signals continued investor appetite for AI‑first biotech platforms capable of delivering rapid program throughput. Note on terminology: bispecifics and ADCs are engineered antibody formats that target two molecules or deliver cytotoxic payloads to tumors, respectively.